Abstract:Ischemia-reperfusion injury (IRI), critically involved in the pathology of reperfusion therapy for myocardial infarction, is closely related to oxidative stress the inflammatory response, and disturbances in energy metabolism. Emerging evidence shows that metabolic imbalances of iron participate in the pathophysiological process of cardiomyocyte IRI [also termed as myocardial ischemia-reperfusion injury (MIRI)]. Iron is an essential mineral required for vital physiological functions, including cellular respiration, lipid and oxygen metabolism, and protein synthesis. Nevertheless, cardiomyocyte homeostasis and viability are inclined to be jeopardized by iron-induced toxicity under pathological conditions, which is defined as ferroptosis. Upon the occurrence of IRI, excessive iron is transported into cells that drive cardiomyocytes more vulnerable to ferroptosis by the accumulation of reactive oxygen species (ROS) through Fenton reaction and Haber–Weiss reaction. The increased ROS production in ferroptosis correspondingly leads cardiomyocytes to become more sensitive to oxidative stress under the exposure of excess iron. Therefore, ferroptosis might play an important role in the pathogenic progression of MIRI, and precisely targeting ferroptosis mechanisms may be a promising therapeutic option to revert myocardial remodeling. Notably, targeting inhibitors are expected to prevent MIRI deterioration by suppressing cardiomyocyte ferroptosis. Here, we review the pathophysiological alterations from iron homeostasis to ferroptosis together with potential pathways regarding ferroptosis secondary to cardiovascular IRI. We also provide a comprehensive analysis of ferroptosis inhibitors and initiators, as well as regulatory genes involved in the setting of MIRI.

Ferroptosis: Opportunities and Challenges in Myocardial Ischemia-Reperfusion Injury

Ferroptosis and Its Multifaceted Roles in Cerebral Stroke

The molecular mechanisms and potential drug targets of ferroptosis in myocardial ischemia–reperfusion injury

Ferroptosis and myocardial ischemia-reperfusion: mechanistic insights and new therapeutic perspectives

Ferroptosis and Renal Fibrosis: A New Target for the Future (Review)

Insight into the Role of Ferroptosis in Non-neoplastic Neurological Diseases

Myocardial Ischemia/Reperfusion Injury: Mechanism and Targeted Treatment for Ferroptosis

Ferroptosis in organ ischemia–reperfusion injuries: recent advancements and strategies

Multifaceted Role of Ferroptosis in Cardiovascular Disease

A Novel Insight Into the Fate of Cardiomyocytes in Ischemia-Reperfusion Injury: From Iron Metabolism to Ferroptosis

Targeting ferroptosis: a novel insight against myocardial infarction and ischemia-reperfusion injuries

Targeting Ferroptosis: Pathological Mechanism and Treatment of Ischemia-Reperfusion Injury

Ferroptosis as a novel therapeutic target for cardiovascular disease

Molecular therapy of cardiac ischemia–reperfusion injury based on mitochondria and ferroptosis

Targeting Ferroptosis as a Promising Therapeutic Strategy for Ischemia-Reperfusion Injury

Ferroptosis: a new target for hepatic ischemia-reperfusion injury?

Ferroptosis: past, present and future

Ferroptosis in Cardiovascular Disease and Cardiomyopathies: Therapeutic Implications of Glutathione and Iron Chelating Agents

Fighting ischemia-reperfusion injury: Focusing on mitochondria-derived ferroptosis

Ferroptosis, a Regulated Form of Cell Death, as a Target for the Development of Novel Drugs Preventing Ischemia/Reperfusion of Cardiac Injury, Cardiomyopathy and Stress-Induced Cardiac Injury

Acetylation, ferroptosis, and their potential relationships: Implications in myocardial ischemia-reperfusion injury